Meribank Biotech Co., Ltd (TPEX:4724)
Taiwan · Delayed Price · Currency is TWD 8.88
-0.44 (-4.72%)
Aug 26, 2026, 1:09 PM CST
Meribank Biotech Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 408.48 | 471.76 | 366.43 | 234.34 | 180.12 | 163.08 |
Revenue Growth | -13.41% | 28.75% | 56.36% | 30.10% | 10.45% | -16.11% |
Gross Profit Gross Profit Growth | 142.93 | 202.18 | 193.94 | 138.87 | 94.77 | 90.06 |
Operating Income Operating Income Growth | -105.68 | -52.78 | -87.9 | -122.36 | -109.78 | -97.22 |
Net Income Net Income Growth | -135.08 | -81.47 | -94.71 | -125.35 | -102.13 | -99.19 |
Earnings Per Share EPS Growth | -1.41 | -0.89 | -1.19 | -1.99 | -1.63 | -1.64 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Management Consulting Department Management Consulting Department Growth | 159.76 | 88.24 | - | - | - |
Other Other Growth | 65.85 | 50.16 | 26.9 | 17.04 | - |
Stem Cell Department Stem Cell Department Growth | 246.16 | 228.03 | 207.44 | 163.09 | 163.08 |
Total Total Growth | 471.76 | 366.43 | 234.34 | 180.12 | 163.08 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 191.32 | 229.34 | 165.09 | 399.46 | 207.86 | 286.25 |
Total Debt Total Debt Growth | 1,078 | 1,128 | 942.84 | 34.04 | 45.83 | 52.97 |
Net Cash (Debt) Net Cash Growth | -886.26 | -898.33 | -777.75 | 365.42 | 162.03 | 233.28 |
Net Cash Growth | - | - | - | 125.53% | -30.54% | 752.06% |
Net Cash Per Share Net Cash Per Share Growth | -9.25 | -9.84 | -9.78 | 5.81 | 2.58 | 3.87 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 70.04 | 89.45 | -38.09 | -29.7 | -41.33 | -23 |
Capital Expenditures CapEx Growth | -7.53 | -3.84 | -248.61 | -5.8 | -4.15 | -7.21 |
Free Cash Flow Free Cash Flow Growth | 62.51 | 85.62 | -286.7 | -35.5 | -45.48 | -30.2 |
Free Cash Flow Growth | -26.99% | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 34.99% | 42.86% | 52.93% | 59.26% | 52.62% | 55.22% |
Operating Margin | -25.87% | -11.19% | -23.99% | -52.21% | -60.95% | -59.61% |
Pretax Margin | -34.94% | -18.85% | -27.71% | -55.45% | -57.31% | -60.83% |
Profit Margin | -33.07% | -17.27% | -25.85% | -53.49% | -56.70% | -60.83% |
FCF Margin | 15.30% | 18.15% | -78.24% | -15.15% | -25.25% | -18.52% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
P/FCF Ratio | 14.31 | 16.80 | - | - | - | - |
PS Ratio | 2.19 | 3.05 | 6.72 | 10.21 | - | - |